Director, Biostatistics
Boost your chances before you apply.
Celcuity
US
Summary
The Director of Biostatistics will lead and coordinate statistical activities for clinical trials, including study design, analysis, and regulatory reporting. They will also provide oversight for statistical programming, CRO deliverables, and cross-functional team collaboration.
Job Description
Reporting to the Vice President, Biostatistics and Data Management, the Director, Biostatistics will focus on actively contributing to efforts across multiple studies, analyzing and reporting on any or all parts of clinical studies. The role will have oversight of statistical programming and deliverables that contribute to the quality assurance and control of statistical analyses, writing methods and analysis descriptions in formal reports, communicating with collaborators, and organizing and maintaining confidential project materials.
Responsibilities:
- Lead and coordinate statistical related activities to support clinical studies including but not limited to supporting the design, execution, analysis, interpretation, and reporting of clinical trials as well as communication of data evidence.
- Support for the statistical aspects of business-critical and/or regulatory commitments, provides input to program plans, and represents the Biostatistics function for cross-functional and intra-departmental teams or working groups.
- Prepare or review the clinical study protocols, case report forms, statistical analysis plans, and table shells as needed.
- Create or validate SAS programs for data management activities, compliant analysis datasets, and statistical analysis of the clinical trial data.
- Prepare the statistical section of clinical trial reports and presentations of the results to the team.
- Demonstrate solid understanding of regulatory guidance and statistical methodology as applied to clinical studies in pharmaceutical development.
- Writing statistical reports and memos with minimal guidance.
- Validating complex datasets or summary tables.
- Oversight CRO on statistical deliverables
- Other duties as assigned.
Qualifications:
- Master's Degree in statistics, biostatistics or a closely related field; PhD preferred.
- 7+ years clinical trials experience with at least 2 years in oncology clinical trials.
- Experience with solid tumor oncology and global NDA/BLA submissions preferred.
- Experience with design, execution, and reporting phase 3 oncology clinical trials as a lead statistician preferred.
- Strong knowledge of statistical software packages including SAS and R. Other statistical analysis and reporting applications such as Splus and SQL are plus.
- Ability to write and articulate clearly.
- Strong sense of urgency and commitment to excellence in the successful achievement of defined project objectives.
- Ability to prioritize workload to meet multiple delivery timelines.
- Excellent planning and organization skills.
- Excellent problem-solving abilities.
- Ability to function independently and exercise judgment and decision-making skills.
- Continuous improvement mindset; seeking ways to drive innovation and efficiencies throughout the organization.
- Flexible and willing to learn; adapting to business and site needs in a dynamic environment.
- Maintain a positive, approachable and professional attitude.
About Celcuity:
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.
Celcuity is an Equal-Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $195,000 to $215,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.
Notice to Recruiters/Staffing Agencies
Recruiters and staffing agencies should not contact Celcuity through this page. All recruitment vendors (search firms, recruitment agencies, and staffing companies) are prohibited from contacting our hiring manager(s), executive team members, or employees directly.
We require that all recruiters and staffing agencies have a fully executed, formal written agreement on file. Celcuity’s receipt or acceptance of an unsolicited resume submitted by a vendor organization to this website or employee does not constitute an actual or implied contract between Celcuity and such organization and will be considered unsolicited. Celcuity will not be responsible for related fees.
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN